Clene Inc. (NASDAQ:CLNN) Receives $32.60 Consensus Target Price from Analysts

Clene Inc. (NASDAQ:CLNN) has been assigned an average rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $32.60.

A number of research firms have recently commented on CLNN. Benchmark reissued a “buy” rating on shares of Clene in a report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research note on Friday, January 9th. UBS Group restated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Finally, D. Boral Capital reiterated a “buy” rating and set a $23.00 price target on shares of Clene in a report on Friday, January 9th.

Clene Stock Up 4.6%

Shares of Clene stock opened at $4.73 on Tuesday. Clene has a 12-month low of $2.28 and a 12-month high of $13.50. The company has a market capitalization of $51.32 million, a price-to-earnings ratio of -1.40 and a beta of 0.81. The firm’s 50-day moving average price is $5.29 and its two-hundred day moving average price is $6.58.

Insider Activity at Clene

In related news, major shareholder Chidozie Ugwumba sold 72,748 shares of Clene stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $6.73, for a total transaction of $489,594.04. Following the sale, the insider directly owned 521,620 shares in the company, valued at $3,510,502.60. This trade represents a 12.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David J. Matlin bought 33,333 shares of Clene stock in a transaction on Tuesday, January 13th. The shares were acquired at an average cost of $6.50 per share, for a total transaction of $216,664.50. Following the completion of the acquisition, the director directly owned 477,824 shares in the company, valued at approximately $3,105,856. The trade was a 7.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold 525,239 shares of company stock valued at $3,144,162 in the last ninety days. 35.30% of the stock is currently owned by insiders.

Institutional Trading of Clene

A number of institutional investors and hedge funds have recently bought and sold shares of CLNN. SymBiosis Capital Partners LLC acquired a new position in Clene during the 4th quarter worth about $4,523,000. Scoggin Management LP raised its position in shares of Clene by 75.1% during the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after acquiring an additional 107,250 shares during the last quarter. Ensign Peak Advisors Inc lifted its stake in shares of Clene by 668.6% in the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock worth $671,000 after acquiring an additional 99,481 shares during the period. Geode Capital Management LLC lifted its stake in shares of Clene by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock worth $482,000 after acquiring an additional 6,090 shares during the period. Finally, Lunt Capital Management Inc. boosted its holdings in Clene by 2.5% in the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after acquiring an additional 1,250 shares during the last quarter. 23.28% of the stock is currently owned by institutional investors and hedge funds.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).